Missense mutations are usually CRIM-positive unless the nucleotide affects a splice junction, or the change is in the first ATG codon of the gene, which can result in CRIM-negative status. therapy (ERT)[4],[5]. About 30% of patients with IPD make no detectable GAA protein based on Western blot analysis using skin fibroblasts, and are classified as CRIM-negative[5],[6]. These patients usually fare poorly due to the development of high, sustained anti-rhGAA IgG antibodies that significantly reduce the efficacy of ERT. In contrast, CRIM-positive patients with IPD make some residual GAA protein, although with severely reduced or deficient GAA activity. They usually PROTAC ERRα ligand 2 have low antibody titers and a better clinical outcome, however a subset of CRIM-positive cases also develop high sustained antibody titers[4]. Immune tolerance induction (ITI) for CRIM-negative patients, which prevents the production of anti-rhGAA IgG antibodies, is most effective when initiated in the ERT-nave setting with PROTAC ERRα ligand 2 the first dose of ERT[7]. This observation, coupled with the knowledge that early treatment in IPD results in the best prognosis, offers necessitated development of a rapid method for determining CRIM status. Historically, CRIM status for IPD patients continues to be determined using Western blot analysis of skin PROTAC ERRα ligand 2 fibroblast lysates; different bands representing inactive precursor (110 kDa), intermediate type (95 kDa), and active forms (76 and 70 kDa) of GAA can be distinguished in normal skin fibroblast protein[8],[9],[10],[11]. However , this process takes several weeks due to the time needed for culturing skin fibroblasts from skin biopsy tissue. In addition , some patients may make small amounts of GAA protein that are below the limits of detection by Western blot[6]. Recently, we have published that CRIM status can be predicted based onGAAgene mutations for over 90% of patients[12]. For example , premature stop codons caused by nonsense or frameshift mutations usually result in CRIM-negative alleles, and missense mutations typically result in CRIM-positive alleles. However , these predictions depend on the specific mutation, and prediction of CRIM status may not be possible or accurate for novel mutations in all patients. Therefore , a fast, accurate method of CRIM determination for all IPD patients would be beneficial. A new method for determining CRIM status, using peripheral blood mononuclear cells (PBMCs) continues to be reported recently[13], with promising results in a small group of patients. Here, we present results obtained using the same method to determine CRIM status in 33 IPD patients and comparison of those results with CRIM status predicted byGAAmutations, and/or CRIM status determined using skin fibroblasts, where available. == 2 . Patients and methods == All subjects were diagnosed with Pompe disease and were enrolled in a Duke Medicine Institutional Review Board-approved protocol (IRB#Pro00001562; LDN6709 Site 206; Clinicaltrials. govIdentifier: NCT01665326). Samples for analysis were sent from across the USA to the Duke Biochemical Genetics Laboratory. CRIM status was determined by Western blot analysis of PBMCs and cultured skin fibroblast protein, as previously published[12],[13]. Specifically, blood samples intended for PBMC analysis were collected in BD Vacutainer CPT (Cell Preparation Tube) with Sodium Citrate (Becton Dickinson, REF 362760, Franklin Lakes, New Jersey). Upon arrival in the laboratory, PBMCs were isolated within 2448 h of sample collection when possible. Cell lysates were prepared and Western blot analysis performed as previously described[13]. SPP1 None from the patients in PROTAC ERRα ligand 2 this study were on ERT at the time of sample collection. Protein samples from normal human fibroblasts, normal human PBMCs and known affected Pompe patients were used as the assay control intended for comparison (Corielle Institute intended for Medical Resarch, Camden, NJ). -actin antibody was used as a loading control and to assess the integrity from the patient protein samples[13]. Sequence analysis of theGAAgene (NM_000152) was performed in a CLIA and CAP certified laboratory. To predict CRIM status fromGAAmutations, we used our database which correlatesGAAmutations and CRIM status of about 140 patients with IPD[12]. If a mutation had been previously found in a CRIM-negative patient, it was designated as CRIM-negative. If a mutation had previously been found in homozygous state in a CRIM-positive patient, it was designated as CRIM-positive. If a mutation was not in our database, or was in.
